Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to improve hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRTO
Previous Symbol
CUSIPN/A
Phone781-890-0102
Debt
Debt-to-Equity RatioN/A
Current Ratio10.70
Quick Ratio10.70
Price-To-Earnings
Trailing P/E Ratio-0.78
Forward P/E Ratio-1.44
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.17 per share
Price / Book9.76
Profitability
EPS (Most Recent Fiscal Year)($2.13)
Net Income$-29,960,000.00
Net MarginsN/A
Return on Equity-293.80%
Return on Assets-61.05%
Miscellaneous
Employees16
Outstanding Shares19,220,000
Market Cap$31.72 million
OptionableNot Optionable
Proteon Therapeutics (NASDAQ:PRTO) Frequently Asked Questions
What is Proteon Therapeutics' stock symbol?
Proteon Therapeutics trades on the NASDAQ under the ticker symbol "PRTO."
How were Proteon Therapeutics' earnings last quarter?
Proteon Therapeutics Inc (NASDAQ:PRTO) issued its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.30) by $0.05. View Proteon Therapeutics' Earnings History.
When is Proteon Therapeutics' next earnings date?
What price target have analysts set for PRTO?
5 analysts have issued 12-month price objectives for Proteon Therapeutics' shares. Their forecasts range from $3.00 to $5.00. On average, they expect Proteon Therapeutics' share price to reach $3.6667 in the next year. This suggests a possible upside of 120.9% from the stock's current price. View Analyst Price Targets for Proteon Therapeutics.
What is the consensus analysts' recommendation for Proteon Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteon Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Proteon Therapeutics.
Has Proteon Therapeutics been receiving favorable news coverage?
News stories about PRTO stock have trended neutral this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Proteon Therapeutics earned a media sentiment score of 0.0 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next several days.
Who are some of Proteon Therapeutics' key competitors?
Some companies that are related to Proteon Therapeutics include Applied Genetic Technologies (AGTC), Fennec Pharmaceuticals (FENC), Organovo (ONVO), Cidara Therapeutics (CDTX), BioCardia (BCDA), Aevi Genomic Medicine (GNMX), Aptose Biosciences (APTO), Oncobiologics (ONS), Brainstorm Cell Therapeutics (BCLI), Entera Bio (ENTX), Genocea Biosciences (GNCA), Curis (CRIS), TRACON Pharmaceuticals (TCON), BIONDVAX PHARMA/S (BVXV) and Vical (VICL).
Who are Proteon Therapeutics' key executives?
Proteon Therapeutics' management team includes the folowing people:
- Mr. Timothy P. Noyes, Pres, CEO & Director (Age 56)
- Mr. George A. Eldridge, Sr. VP, CFO, Treasurer & Assistant Sec. (Age 55)
- Dr. Steven Keith Burke, Sr. VP & Chief Medical Officer (Age 57)
- Mr. Matthew P. Kowalsky, VP of Legal & Sec. (Age 45)
- Mr. Daniel P. Gottlieb, VP of Corp. Devel. (Age 48)
Who are Proteon Therapeutics' major shareholders?
Proteon Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (1.25%). Company insiders that own Proteon Therapeutics stock include George Arthur Eldridge, James E Flynn and Steven Keith Burke. View Institutional Ownership Trends for Proteon Therapeutics.
Which institutional investors are selling Proteon Therapeutics stock?
How do I buy shares of Proteon Therapeutics?
Shares of PRTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Proteon Therapeutics' stock price today?
One share of PRTO stock can currently be purchased for approximately $1.66.
How big of a company is Proteon Therapeutics?
Proteon Therapeutics has a market capitalization of $33.64 million. The biopharmaceutical company earns $-29,960,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Proteon Therapeutics employs 16 workers across the globe.
What is Proteon Therapeutics' official website?
How can I contact Proteon Therapeutics?
Proteon Therapeutics' mailing address is 200 WEST STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 781-890-0102 or via email at [email protected]
MarketBeat Community Rating for Proteon Therapeutics (NASDAQ PRTO)
MarketBeat's community ratings are surveys of what our community members think about Proteon Therapeutics and other stocks. Vote "Outperform" if you believe PRTO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTO will underperform the S&P 500 over the long term. You may vote once every thirty days.
